Address
Email address
Phone number
Website
https://www.repligen.com/Repligen | Inspiring advances in bioprocessingOur mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.
Name
Repligen Estonia OÜ
Registry code
14121227
VAT number
EE101911580
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
27.09.2016 (8)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
71129 - Other engineering-technical activities
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Madis Unt 26.11.1983 (40) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member |
| 2019 31.03.2022 | 2020 31.03.2022 | 2021 14.03.2023 | 2022 02.05.2023 | |
|---|---|---|---|---|
| Total Revenue | 879 990 € | 10 867 606 € | 9 028 285 € | 9 560 606 € |
| Net profit (loss) for the period | -1 390 488 € | 1 763 006 € | 28 348 € | 867 637 € |
| Profit Margin | -158% | 16% | 0% | 9% |
| Current Assets | 759 170 € | 8 127 707 € | 5 300 770 € | 7 824 185 € |
| Fixed Assets | 106 584 € | 94 280 € | 211 791 € | 1 065 177 € |
| Total Assets | 865 754 € | 8 221 987 € | 5 512 561 € | 8 889 362 € |
| Current Liabilities | 1 892 547 € | 4 170 774 € | 2 063 000 € | 4 572 164 € |
| Non Current Liabilities | 415 000 € | 3 730 000 € | 3 100 000 € | 3 100 000 € |
| Total Liabilities | 2 307 547 € | 7 900 774 € | 5 163 000 € | 7 672 164 € |
| Share Capital | - | - | - | - |
| Equity | -1 441 793 € | 321 213 € | 349 561 € | 1 217 198 € |
| Employees | 17 | 31 | 35 | 47 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 4 421 607.3 € | 345 177.26 € | 362 958.13 € | 56 |
| 2023 Q4 | 3 915 895.12 € | 309 589.09 € | 330 524.25 € | 55 |
| 2023 Q3 | 1 897 382.07 € | 298 241.81 € | 318 173.65 € | 53 |
| 2023 Q2 | 3 814 563.46 € | 378 664.36 € | 403 486.86 € | 51 |
| 2023 Q1 | 743 381.96 € | 271 197.44 € | 287 645.11 € | 49 |
| 2022 Q4 | 2 583 908.55 € | 260 335.49 € | 276 046.93 € | 47 |
| 2022 Q3 | 1 057 689.18 € | 249 563.39 € | 264 786.36 € | 48 |
| 2022 Q2 | 2 203 330.23 € | 417 590.71 € | 435 941.66 € | 45 |
| 2022 Q1 | 2 011 283.95 € | 196 195.96 € | 208 844 € | 44 |
| 2021 Q4 | 1 931 107.25 € | 176 690.4 € | 186 648.43 € | 39 |
| 2021 Q3 | 3 423 459.43 € | 199 599.06 € | 212 007.71 € | 38 |
| 2021 Q2 | 1 102 486.26 € | 164 670.85 € | 176 435.99 € | 38 |
| 2021 Q1 | 3 824 508.03 € | 176 546.01 € | 188 629.65 € | 35 |
| 2020 Q4 | 6 614 060.59 € | 2 420.56 € | 173 686.33 € | 34 |
| 2020 Q3 | 447 257.14 € | 75 094.79 € | 131 196.07 € | 37 |
| 2020 Q2 | 594 472.88 € | - | 106 552.87 € | 32 |
| 2020 Q1 | 461 158.8 € | 81 037.11 € | 107 253.62 € | 25 |
